Vertex is extending its lead in the cystic fibrosis space and setting a premium price for its next-generation triple-combination product Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), which it intends to gradually replace its blockbuster Trikafta (elexacaftor/tezacaftor/ivacaftor). The Boston-based company set a wholesale acquisition cost (WAC) of $370,269 a year for Alyftrek, roughly a 7% premium over Trikafta’s US pricing.
Key Takeaways
- Vertex obtained US FDA approval for Alyftrek, a triplet therapy for cystic fibrosis that it hopes to switch patients to from Trikafta.
- The new triplet demonstrated non-inferiority to Trikafta on a lung-function endpoint in Phase III, as well as superiority on the surrogate marker of sweat-chloride reduction
The 20 December US Food and Drug Administration approval gave Vertex some good news on the heels of a clinical development setback for its non-opioid pain candidate suzetrigine (VX-548), which failed a Phase II trial in lumbosacral radiculopathy (LSR) on 19 December.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?